Chutes & Ladders—CMO walks out on troubled Immunomedics

Following a rejection from the FDA, Immunomedics is now losing its research lead. Formerly an AstraZeneca cancer research executive, Iannone joined the company last April to help focus its oncology pipeline, after the troubled biotech saw a potential $2 billion deal fall through with Seattle Genetics—and after the board axed former President and CEO Cynthia Sullivan. According to the company, Iannone “has decided to leave the company to pursue a career opportunity close to his home in Pennsylvania,” after many years of working elsewhere.